The Intravenous Immunoglobulin (IVIg) Market is witnessing steady growth as healthcare providers increasingly use immunoglobulin therapies for immunodeficiency, autoimmune, neurological, and other disorders. According to Market Research Future, the market was valued at USD 12.39 billion in 2024 and is projected to grow from USD 12.88 billion in 2025 to USD 18.99 billion by 2035, representing a CAGR of 3.96%.

Increasing awareness of immunotherapy and the rising prevalence of immune-related diseases are important factors supporting market expansion. IVIG therapies provide concentrated antibodies derived primarily from human plasma and are used in the management of several immune and neurological conditions.

Hospitals remain the largest end-use segment, accounting for approximately 63% of the market, supported by specialized infrastructure and trained healthcare professionals. Human plasma is the dominant source segment, representing around 68% of the market. Immunodeficiency disorders also hold the leading application position with approximately 57% share.

North America is a leading regional market, supported by advanced healthcare infrastructure, high treatment adoption, and established pharmaceutical capabilities. Europe and Asia-Pacific also present significant opportunities as healthcare access and awareness continue improving.

Technological advancements in plasma fractionation, purification, and manufacturing processes are expected to improve product quality and safety. Growing demand for personalized treatment and homecare-based therapies may further create opportunities for market participants.

Explore additional reports to understand evolving market landscapes:

Radiation Protection Apparels Market Size

Radiation Protection Apparels Market Share

Radiation Protection Apparels Market Trends

Radiation Protection Apparels Market Growth

Prp Prf In Cosmetics Market Demand